Dapagliflozin — Dosing in CKD & Dialysis

Dapagliflozin (SGLT2 Inhibitor): renal dosing adjustments, dialyzability (Removal by hemodialysis has not been studied (Farxiga label section 10). Level estimated from molecule size or protein binding; not measured.), and renal-relevant safety risk for CKD and dialysis patients. Educational referenc

Reviewed by Matt · November 16, 2026

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.